Europe's top universities threaten €2 billion pharma innovation project boycott
This article was originally published in Scrip
Twenty-two leading research-intensive universities in Europe have strongly criticised the €2 billion Innovative Medicines Initiative (IMI), a public-private partnership set up by the European Commission (EC) and the European pharmaceutical industry association (EFPIA) to overcome research bottlenecks in drug development, saying it gives funding and intellectual property right (IPR) disadvantages to academics and SMEs.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.